Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [40]](https://figures.cochat.ai/paper-figures/21d83ef63bbb4a5890ce9f40e21450f3/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses of 13 randomized clinical trials evaluating the CV effects of metformin vs. placebo or active control, including the data from the UKPDS, none of the differences in assessed CV outcomes was statistically significant.184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“This Class IIa recommendation for metformin is based on the weight of opinion rather than the weight of evidence; results from meta-analyses of observational studies suggest associations with better CV outcome, but this is not supported by results from meta-analyses restricted to randomized trials in patients with T2DM and ASCVD, where no statistically significant effect of metformin has been”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
In the citing paper
“The pooled HRs (95% CIs) were: all-cause mortality 0.96 (0.84-1.09);CV death 0.97 ( 0.80-1.16); MI 0.89 (0.75-1.06); stroke 1.04 (0.73-1.48); and peripheral vascular disease 0.81 (0.50-1 31).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin reduced the incidence of diabetes by 31% among people with glucose levels just below the diagnostic threshold in the US Diabetes Prevention Programme [36], and by 26% in the Indian equivalent [37].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 10×
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“This contrasts with the evidence now available for newer and more expensive glucose-lowering drugs, such as empagliflozin [34] and liraglutide [10], and of course for medications targeting different risk factors, for example statins.”
BackgroundEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974 · cited 1×
“While acknowledging that metformin has pleiotropic effects, if it was shown to be effective in such a trial, the near-linear relationship between HbA1c and risk of cardiovascular disease and death [39], and the somewhat arbitrary diagnostic threshold for diabetes, might also reinforce the reputation of metformin for t…”
BackgroundBoussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“However, subsequent randomised trials evaluating the effects of intensive treatment for the regulation of blood glucose have highlighted concerns about adverse effects, in particular hypoglycaemia and mortality, and demonstrated inconsistent findings for risk of micro- and macrovascular complications [2, 3].”
BackgroundMetformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA · doi:10.1001/jama.2014.15298 · Cited by 601
Zoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440 · cited 9×
“58 Kooy et al (2009) [22] UKPDS (1998) [12] Holman et al (2008) [21]”
BackgroundInfluentialHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386 · cited 1×
“However, subsequent randomised trials evaluating the effects of intensive treatment for the regulation of blood glucose have highlighted concerns about adverse effects, in particular hypoglycaemia and mortality, and demonstrated inconsistent findings for risk of micro- and macrovascular complications [2, 3].”
BackgroundLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300 · cited 2×
“08], respectively) more strongly favoured metformin [29], mainly because of the inclusion of the open-label, active-comparator trial, the Comparative Outcomes Study of Metformin Intervention versus Conventional (COSMIC) Approach Study [30].”
BackgroundResultBoussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., & Cornu, C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001204 · Cited by 266
Horton, E. S., Clinkingbeard, C., Gatlin, M., Foley, J., Mallows, S., & Shen, S. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1660 · Cited by 241
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
for the Diabetes Prevention Program Research Group, Aroda, V. R., Knowler, W. C., Crandall, J. P., Perreault, L., Edelstein, S. L., Jeffries, S. L., Molitch, M. E., Pi-Sunyer, X., Darwin, C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4361-9 · Cited by 194
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Sipilä, H., Oksanen, A., Viljanen, T., Rönnemaa, T., Viikari, J., Knuuti, J., & Nuutila, P. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3479 · Cited by 165
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
Seltzer, H. S. (1972) · Diabetes · doi:10.2337/diab.21.9.976 · Cited by 148
Cryer, D. R., Nicholas, S. P., Henry, D. H., Mills, D. J., & Stadel, B. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.539 · Cited by 146
Rachmani, R., Slavachevski, I., Levi, Z., Zadok, B.-S., Kedar, Y., & Ravid, M. (2002) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(02)00131-0 · Cited by 134
Hemmingsen, B., Christensen, L. L., Wetterslev, J., Vaag, A., Gluud, C., Lund, S. S., & Almdal, T. (2012) · BMJ · doi:10.1136/bmj.e1771 · Cited by 108
Chiasson, J.-L., Naditch, L., & for the Miglitol Canadian University Investigator Group (2001) · Diabetes Care · doi:10.2337/diacare.24.6.989 · Cited by 98
Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4227-1 · Cited by 72
Metformin as firstline treatment for type 2 diabetes: are we sure?
Boussageon, R., Gueyffier, F., & Cornu, C. (2016) · BMJ · doi:10.1136/bmj.h6748 · Cited by 39
Hermann, L. S., KALÉN, J., Katzman, P., Lager, I., Nilsson, A., Norrhamn, O., Sartor, G., & Ugander, L. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00160.x · Cited by 35
Pharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes
Gram, J., Henriksen, J. E., Grodum, E., Juhl, H., Hansen, T. B., Christiansen, C., Yderstræde, K., Gjessing, H., Hansen, H. M., Vestergaard, V., et al. (2011) · Diabetes Care · doi:10.2337/dc10-0531 · Cited by 35
Pladevall, M., Riera-Guardia, N., Margulis, A. V., Varas-Lorenzo, C., Calingaert, B., & Perez-Gutthann, S. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0187-5 · Cited by 34
Cited by
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Metadata
- Authors
- Griffin, S. J., Leaver, J. K., & Irving, G. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Griffin, Simon J.
- Venue
- Diabetologia
- Published
- 2017-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1620-1629
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552849
- OpenAlex
- W2740802742
- Cited by
- 398
- References
- 45
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 31 · 2022: 52 · 2021: 60 · 2020: 75 · 2019: 64 · 2018: 39 · 2017: 8
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- University of Cambridge
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, cardiovascular disease, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, peripheral vascular disease, ischemic heart disease, UK Prospective Diabetes Study, lifestyle intervention, drug effectiveness, cardiovascular risk reduction, glycemic control, randomized controlled trials, meta-analysis of trials, study heterogeneity, publication bias
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.